Lori Confino is a well-known and highly respected attorney in the hi-tech and biotech industries. Maintaining a clear view of all the shades and nuances that make up this complex world, Lori brings practical business sense to corporate and commercial transactions. Lori has over three decades of experience in corporate and commercial transactions with an emphasis on venture capital and private equity investment transactions, alongside extensive expertise guiding and advising entrepreneurs and early-stage start-ups from first seed financing, via a full range of day-to-day legal services through to the acquisition, merger or initial public offering and beyond.

Neomi Enoch, CPA, MBA Neomi is a business consultant, bringing a vast experience as a CFO in global companies traded at NASDAQ and Tel Aviv stock exchange.

Neomi led the IPO of Parter communication at NASDAQ, and The IPO of Mul-T-Lock in Tel Aviv Stock Exchange and raised funds from capital market as CFO of Meuhedet HMO and Supesal Ltd.

Neomi serves as a director at Mekorot Water Company, Kalil industries Ltd, Exel solutions group and S.R. Accord Ltd

Neomi is a CPA holds an M.B.A from Bradford University, cum laud and B.A from Tel Aviv University.

Doron serves as the chairman and a director in a variety of technology companies, mainly in medical device companies.
In the past, Doron served as the CEO of Elron (Nasdaq: ELRNF, TASE: ELRN) and as the chairman and director of Given Imaging (previously traded at Nasdaq: GIVN; TASE: GIVN) until it was sold to Covidien (now Medtronic) for approximately USD 1 billion.

Suzana Nahum-Zilberberg is a seasoned executive with a vast managerial and leadership experience in the healthcare industry across global companies and early-stage companies. With financial expertise and experience as a board member in various companies.

Ms. Nahum-Zilberberg is a strategic advisor and the Chairman of The Activity Based Therapy (ABT) Center Foundation for Neurorehabilitation. She served as the CEO of BioLight Life Sciences Ltd. (BOLT/TASE) between the years 2011-2020, Prior to joining BioLight, Ms. Nahum-Zilberberg held several senior positions at Teva Pharmaceuticals Industries, including Vice President of Asia and Pacific and Director in the office of the President and CEO.

Ms. Nahum-Zilberberg holds a B.A. degree in accounting and economics and a M.B.A. degree, both from Tel Aviv University, a Certified Director degree from Tel Aviv University, and studied at the INSEAD Asian International Executive Program. She is a certified public accountant.

Stanley Hirsch is a biotech and pharma CEO and Board Director with significant experience across biopharmaceutical and agricultural biotech fields.  He has extensive executive and board level experience in private and publicly listed companies on US and UK exchanges, direct experience raising capital and leading Mergers & Acquisitions.

Alon Sinai brings over 25 years of operational and managerial experience in medical corps of the Israeli Defense Forces. He holds a Master’s degree in Health Systems Management and a Bachelor’s degree in emergency medicine.

Professor Dvir obtained his Ph.D. in Biotechnology Engineering from Ben Gurion University of the Negev in Israel. His Ph.D. research focused on cardiac tissue engineering and regeneration. Prof. Dvir continued his postdoctoral studies in the laboratory of Professor Robert Langer in the Department of Chemical Engineering at MIT. His postdoctorial research focused on nanotechnological strategies for engineering complex tissues. In 2011, Professor Dvir was recruited by the Department of Biotechnology and the center for Nanotechnology at Tel Aviv University to establish the Laboratory for Tissue Engineering and Regenerative Medicine. In 2013, he joined the newly established Department of Materials Science and Engineering at Tel Aviv University, where he has also served as an Associate Professor in the Department of Biotechnology since 2015.